Catalent Inc (NASDAQ:CTLT) SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Christine Dolan also recently made the following trade(s):

  • On Tuesday, August 1st, Christine Dolan sold 745 shares of Catalent stock. The stock was sold at an average price of $34.85, for a total transaction of $25,963.25.

Catalent Inc (CTLT) traded down 1.53% during mid-day trading on Friday, reaching $40.66. 619,942 shares of the company traded hands. The firm has a market capitalization of $5.09 billion and a price-to-earnings ratio of 46.74. The stock’s 50 day moving average price is $35.50 and its 200 day moving average price is $32.67. Catalent Inc has a 52 week low of $21.83 and a 52 week high of $41.46.

Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.57 by $0.08. Catalent had a net margin of 4.88% and a return on equity of 16.95%. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. During the same quarter in the prior year, the firm earned $0.52 EPS. Catalent’s revenue for the quarter was up 15.9% on a year-over-year basis. Equities analysts forecast that Catalent Inc will post $1.60 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/catalent-inc-ctlt-svp-christine-dolan-sells-1594-shares/1536701.html.

Several brokerages recently issued reports on CTLT. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research raised shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 target price for the company in a report on Tuesday, July 4th. Piper Jaffray Companies reissued a “buy” rating and set a $45.00 target price on shares of Catalent in a report on Tuesday. Wells Fargo & Company reissued an “outperform” rating and set a $39.00 target price (up previously from $30.00) on shares of Catalent in a report on Thursday. Finally, Jefferies Group LLC reissued a “hold” rating and set a $38.00 target price (up previously from $35.00) on shares of Catalent in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $36.22.

A number of institutional investors have recently made changes to their positions in the company. Advisor Group Inc. increased its position in shares of Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares during the last quarter. Stifel Financial Corp increased its position in shares of Catalent by 0.9% in the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after buying an additional 96 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Catalent by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,909 shares of the company’s stock worth $309,000 after buying an additional 130 shares during the last quarter. Aperio Group LLC increased its position in shares of Catalent by 0.8% in the second quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after buying an additional 190 shares during the last quarter. Finally, Capstone Asset Management Co. increased its position in shares of Catalent by 2.3% in the second quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after buying an additional 230 shares during the last quarter.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.